ArticleInternational journal of women's health2025
Determining a Treatment Threshold Value for Endometrial Thickness in Women with Breast Cancer Receiving Tamoxifen.
Article in International journal of women's health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Breast cancer is a prevalent malignancy in women that often requires endocrine treatment, such as tamoxifen, which is known to affect endometrial thickness and pose risks of endometrial pathologies. Objective: This study aimed to determine a clinically relevant threshold for transvaginal ultrasound-measured endometrial thickness in breast cancer patients receiving tamoxifen therapy and assess its predictive value for endometrial pathologies. Methods: We analyzed a total of 205 endometrial biopsies from women dichotomized into premenopausal and postmenopausal groups. We assessed the clinical and pathological characteristics in relation to the presence of endometrial pathologies, employing receiver operating characteristic (ROC) curves to evaluate the predictive value of endometrial thickness as a diagnostic marker. Results: Among the study cohort, 11.71% of patients were diagnosed with endometrial hyperplasia, and 3.90% had endometrial cancer. Our findings indicate that women with endometrial pathologies exhibited significantly greater endometrial thickness (P<0.001) in both premenopausal and postmenopausal cohorts. Notably, demographic and clinical factors including age, body mass index, gravidity, parity, comorbidities, duration of tamoxifen use, and abnormal vaginal bleeding did not differ significantly between groups with or without pathology. The ROC analysis yielded an area under the curve (AUC) of 0.845 for premenopausal and 0.759 for postmenopausal patients, establishing cutoff values of 0.95 cm and 0.55 cm, respectively. Conclusion: Our research confirms that endometrial thickness serves as a significant clinical indicator for diagnosing endometrial pathologies in breast cancer patients receiving tamoxifen therapy, underscoring the necessity for risk-based strategies to monitor patients with thickened endometria and advocating for timely hysteroscopic intervention when warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.